X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs DISHMAN PHARMA - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. DISHMAN PHARMA FRESENIUS KABI ONCO./
DISHMAN PHARMA
 
P/E (TTM) x 22.1 25.1 88.2% View Chart
P/BV x 3.1 3.3 93.0% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 FRESENIUS KABI ONCO.   DISHMAN PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
DISHMAN PHARMA
Mar-16
FRESENIUS KABI ONCO./
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs176374 47.0%   
Low Rs79129 60.9%   
Sales per share (Unadj.) Rs37.7197.8 19.1%  
Earnings per share (Unadj.) Rs5.121.2 24.0%  
Cash flow per share (Unadj.) Rs6.734.7 19.4%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs42.5179.9 23.6%  
Shares outstanding (eoy) m158.2380.69 196.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.41.3 265.4%   
Avg P/E ratio x25.011.9 210.5%  
P/CF ratio (eoy) x18.97.2 261.2%  
Price / Book Value ratio x3.01.4 213.8%  
Dividend payout %09.4 0.0%   
Avg Mkt Cap Rs m20,13520,306 99.2%   
No. of employees `0001.20.8 139.0%   
Total wages/salary Rs m7035,355 13.1%   
Avg. sales/employee Rs Th5,176.219,252.7 26.9%   
Avg. wages/employee Rs Th610.46,459.5 9.4%   
Avg. net profit/employee Rs Th699.62,064.1 33.9%   
INCOME DATA
Net Sales Rs m5,96315,961 37.4%  
Other income Rs m18265 6.8%   
Total revenues Rs m5,98116,226 36.9%   
Gross profit Rs m1,4304,103 34.9%  
Depreciation Rs m2581,091 23.6%   
Interest Rs m-26944 -2.8%   
Profit before tax Rs m1,2162,334 52.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m342624 54.9%   
Profit after tax Rs m8061,711 47.1%  
Gross profit margin %24.025.7 93.3%  
Effective tax rate %28.126.7 105.3%   
Net profit margin %13.510.7 126.1%  
BALANCE SHEET DATA
Current assets Rs m5,10211,018 46.3%   
Current liabilities Rs m2,3859,517 25.1%   
Net working cap to sales %45.69.4 484.4%  
Current ratio x2.11.2 184.7%  
Inventory Days Days150110 135.8%  
Debtors Days Days11335 325.2%  
Net fixed assets Rs m5,14816,304 31.6%   
Share capital Rs m158161 98.0%   
"Free" reserves Rs m6,55612,907 50.8%   
Net worth Rs m6,73214,516 46.4%   
Long term debt Rs m9524,189 22.7%   
Total assets Rs m10,38829,805 34.9%  
Interest coverage x-45.83.5 -1,318.8%   
Debt to equity ratio x0.10.3 49.0%  
Sales to assets ratio x0.60.5 107.2%   
Return on assets %7.58.9 84.3%  
Return on equity %12.011.8 101.6%  
Return on capital %14.617.5 83.3%  
Exports to sales %74.524.8 300.4%   
Imports to sales %24.83.7 663.2%   
Exports (fob) Rs m4,4413,956 112.2%   
Imports (cif) Rs m1,477596 247.8%   
Fx inflow Rs m5,2984,952 107.0%   
Fx outflow Rs m1,772697 254.3%   
Net fx Rs m3,5254,255 82.9%   
CASH FLOW
From Operations Rs m1,2742,786 45.7%  
From Investments Rs m-1,204-1,529 78.8%  
From Financial Activity Rs m-196-941 20.8%  
Net Cashflow Rs m-126316 -39.9%  

Share Holding

Indian Promoters % 0.0 61.4 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 3.7 8.1%  
FIIs % 9.6 12.7 75.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 22.1 41.2%  
Shareholders   42,599 46,261 92.1%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   CADILA HEALTHCARE  UNICHEM LAB  DR. REDDYS LAB  AJANTA PHARMA  ALEMBIC LTD  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS